Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (1821)	2/29/2012 10:50:16 PM
From: dr.praveen	Respond to of 1834

VMAT2 seekingalpha.com PS: I own some

To: Biotech Jim who wrote (1821)	6/7/2012 11:45:02 AM
From: dr.praveen	Read Replies (1) \| Respond to of 1834

Abbott Announces Initiation of Phase 3 Study of Elagolix in Patients with Endometriosis finance.yahoo.com Efficacy will be assessed by a responder analysis for statistical evaluation. The inclusion of a yet unannounced higher dose of elagolix, perhaps 250mg or 300mg (150mg BID) is intriguing. Responder analysis from the phase 2b trial showed an 85% response rate with 150mg elagolix. We believe Abbott is looking for greater than 90% response rate in the phase 3 program through the inclusion of a higher dose.